DV
Dividend Vision

CDXS Stock — Codexis Inc

Codexis Inc (CDXS)

Updated October 16, 2026.

CDXS is a Stock. Total return is -90.6% over the past 16.5 years, 834.3 points behind SPY at 743.7%.

Codexis is a biotechnology company that provides technology solutions for therapeutics manufacturing, using its proprietary CodeEvolver platform to discover and develop novel enzymes and its ECO Synthesis platform for scaled manufacture of RNAi therapeutics. The company has licensing agreements with major pharmaceutical partners including Pfizer. Codexis does not currently have an established distribution schedule.

CDXS performance versus SPY

Price and return data through 2026-10-16.

Total return is -90.6% over the past 16.5 years, 834.3 points behind SPY at 743.7%. Over the past year its total return — price change plus distributions reinvested — is -53.0%. Its deepest 1-year drawdown was 64.5%.

WindowTotal returnCAGR
1M-7.5%—
3M-42.6%—
6M-51.2%—
YTD-23.9%—
1Y-53.0%—
2Y CAGR—-40.70%
3Y CAGR—-14.10%
5Y CAGR—-46.50%
10Y CAGR—-11.80%
Since inception (16.5 years)-90.6%-13.40%

CDXS key facts

Asset type
Stock
Asset class
Equity
Inception date
04/22/2010
Distribution frequency
None
Last close
$1.24 (as of 2026-10-16)
Market cap
$135,787,149
Average volume
980100.0
Beta
2.554
Payout ratio
0.0%
Forward P/E
149.2537
EPS
$-0.33

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CDXS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 64.5%.

Who may consider CDXS — and who may not

It is a weaker fit for investors who need monthly cash flow (CDXS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CDXS

Tagged: Healthcare.

Frequently asked questions

Does CDXS pay monthly?

No. CDXS does not currently distribute.

When does CDXS pay a dividend?

CDXS does not currently distribute.

How has CDXS performed?

Total return is -90.6% over the past 16.5 years, 834.3 points behind SPY at 743.7%. Over the past year its total return — price change plus distributions reinvested — is -53.0%. Its deepest 1-year drawdown was 64.5%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.